Caley Castelein Buys WHWK Shares
Caley Castelein purchased 38,040 shares of WHWK on June 12, 2026.
Key Points
- Caley Castelein purchased 38,040 shares of WHWK on June 12, 2026, with no disclosed price or value.
- WHWK shares traded at $4.16, with peer funds holding substantial positions in the company.
- Analysts from Citizens and Jones Trading initiated buy ratings with targets of $8 and $7 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Caley Castelein made a notable move by purchasing 38,040 shares of WHWK on June 12, 2026. The transaction did not specify a price or total value, but it adds a significant number of shares to Castelein's holdings.
Other Institutional Activity in WHWK
Several institutional investors hold substantial positions in WHWK. QVT Financial LP holds 4,615,709 shares valued at about $15.9 million. OrbiMed Advisors LLC owns 4,166,000 shares, worth approximately $14.4 million. Suvretta Capital Management, LLC has 3,700,000 shares with a value of around $12.8 million. Acuta Capital Partners, LLC maintains 3,410,402 shares valued at roughly $11.8 million, while Avoro Capital Advisors LLC holds 2,849,402 shares worth about $9.8 million.
Whitehawk Therapeutics, Inc. Stock Down 10.0%
Shares of WHWK traded at $4.16. The stock is being monitored by several institutional investors, reflecting interest in its performance and potential.
$WHWK stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders, including Caley Castelein, Neil Desai, Emma Reeve, Richard Maroun, Zhao Baiteng, and Behzad Aghazadeh, each bought 38,040 shares of WHWK. These purchases were not part of a pre-arranged trading plan, indicating direct interest in the company's stock.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of WHWK with a 'buy' rating and a price target of $8. Previously, on December 22, 2025, Jones Trading also initiated a 'buy' rating with a $7 target. This suggests a positive outlook from analysts, with a consensus leaning towards a favorable evaluation of the stock.
About WHWK
WHWK operates in a competitive sector, focusing on delivering innovative solutions. While specific details about its operations and leadership are sparse, the company's activities have attracted attention from both institutional investors and analysts.
Bottom Line
Insider purchases by Caley Castelein and others show confidence in WHWK's prospects. The stock's trading price of $4.16 and recent analyst ratings suggest potential growth. Investors often track such insider activities and analyst opinions to gauge future performance, although it's important to remember that these reports reflect past actions and not necessarily current positions.
Get Whitehawk Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $WHWK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.